-+ 0.00%
-+ 0.00%
-+ 0.00%

Larimar Therapeutics Q1 EPS $(0.31) Beats $(0.54) Estimate

Benzinga·05/14/2026 11:14:07
Listen to the news
Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.54) by 42.59 percent. This is a 32.61 percent increase over losses of $(0.46) per share from the same period last year.